Hi Aggie, LOL! Well, not a whole lot to do except to laugh a little. In a way, I certainly agree that no one should control the access of genomic info in the long run . However, the patenting format of drug [expiration after a number of years, let say,] should deflect the costly undertaking by the private sector, who has beaten the public sector by a mile. Otherwise, no incentive!
I think our Prez and his UK buddy are going to position the dialogue. Fine by me if they just want to talk
Despite I am well underwater, I am more confident than ever
best, Bosco |
